About The Study: This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal RSV vaccine uptake was low, but nirsevimab was effective against RSV-associated hospitalization. There is a potential for substantial public health impact with increased and equitable prevention product coverage in future seasons.
Corresponding Author: To contact the corresponding author, Heidi L. Moline, MD, MPH, email ick6@cdc.gov .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamapediatrics.2024.5572)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.5572?guestAccessKey=c8c52317-1d0c-4ed7-8c77-83f33f2e1782&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=120924
JAMA Pediatrics